Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study

发表于 2026-7-31 17:02:54

期刊：European Journal of Cancer

文献作者：Makoto Tahara; Richard Greil; Danny Rischin; Kevin J. Harrington; Barbara Burtness; Gilberto de Castro; Amanda Psyrri; Irene Brana; Prakash Neupane; Ase Bratland; Thorsten Fuereder; Brett G.M. Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Jianxin Lin; Burak Gumuscu; Nati Lerman; Denis Soulières

出版日期：2025-5-

DOI号：10.1016/j.ejca.2025.115395

下载链接：https://www.sciencedirect.com/sc ... 959804925001765/pdf

文献链接：https://doi.org/10.1016/j.ejca.2025.115395

当前文献来源于 Elsevier BV。

备注信息：

发表于 2026-7-31 17:02:55

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study 一键复制